NSCLC
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
May, 2024
May 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Apr
NSCLC
Apr 26, 2024, 10:07 |
Drugs
Rami Manochakian: U.S. FDA approves adjuvant Alectinib in patients with stage IB-IIIA ALK+Non-Small Cell Lung Cancer
Rami Manochakian, Associate Professor and Thoracic Oncologist at Mayo Clinic, shared on X/Twitter: ''HOT OFF…
Apr 26, 2024, 10:00 |
Insight
Biagio Ricciuti: Our work on long-term outcomes to PD-1 monotherapy by increasing PD-L1 levels in NSCLC is out in JTO and JTO CRR
Biagio Ricciuti, Medical Oncologist at Dana-Farber Cancer Institute, shared on X/Twitter: ''Our work on long-term…
Apr 26, 2024, 09:26 |
Insight
Chul Kim: Thoughtful discussion and great talk by Rachel Sanborn about recent approval of FLAURA2
Chul Kim, Thoracic Medical Oncologist at Georgetown University, shared a post on X/Twitter: ''First-line treatment…
Apr 25, 2024, 19:48 |
Insight
New Paper Alert! The INNOVATED Cohort: The Role of Immune Checkpoint Blockers in Solid Organ Transplant Recipients with Cancer
The INNOVATED Cohort: The Role of Immune Checkpoint Blockers in Solid Organ Transplant Recipients with…
Apr 23, 2024, 18:57 |
Insight
New Paper Alert! Identifying a New EGFR Germline Mutation in Lung Adenocarcinoma: A Case Report and Review of the Literature
Identifying a New EGFR Germline Mutation in Lung Adenocarcinoma: A Case Report and Review of…
Apr 23, 2024, 10:44 |
Blog
Ben Solomon: A timely discussion with Narjust Florez about the ALINA trial
Ben Solomon, Lung Cancer Medical Oncologist at Peter MacCallum Cancer Centre, shared a post by…
Apr 22, 2024, 19:23 |
Insight
New Paper Alert! A Comprehensive Review of ADCs in Lung and Breast Cancer by the ETOP IBCSG Partners Foundation
A Comprehensive Review of ADCs in Lung and Breast Cancer by the ETOP IBCSG Partners…
Apr 22, 2024, 18:48 |
Insight
Piotr Wysocki: Single-agent immunotherapy is a wise choice as first-line treatment in elderly, advanced NSCLC patients, irrespectively of PD-L1 expression
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University…
Apr 22, 2024, 05:14 |
Insight
Chul Kim: In-depth review of BRAF mutant NSCLC by Dr. Marcelo Negrao at Texas Lung 24 Conference
Chul Kim, Thoracic Medical Oncologist at Georgetown University, shared a post on X: "In-depth review…
Apr 21, 2024, 18:13 |
Blog
Antonio Passaro: An intense yet incredibly rewarding day in Oporto
Antonio Passaro, Medical Director with Highly Specialized Position at IEO European Institute of Oncology, shared a…
3
4
5
6
7
All:
126
Posts:
41 - 50
OncoInfluencers: Dialogue with Rob Pieters, hosted by Shushan Hovsepyan
10 Most Promising Cancer Drugs Not Yet Approved: Solid Tumors - 2024 edition by OncoDaily
Elie G. Dib: Excited to share the results of the TAPUR study
OncoInfluencers: Dialogue with Fadlo R. Khuri, hosted by Gevorg Tamamyan
Cedars-Sinai is co-chairing a special AACR conference on transforming the field of Bladder Cancer on May 17-20
Facebook
RSS Feed
Twitter
Linkedin
Youtube